title: Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease.
abstract: Biomarkers and technologies similar to those used in humans are essential for the follow-up of Alzheimer's disease (AD) animal models, particularly for the clarification of mechanisms and the screening and validation of new candidate treatments. In humans, changes in brain metabolism can be detected by 1-deoxy-2-[(18)F] fluoro-D-glucose PET (FDG-PET) and assessed in a user-independent manner with dedicated software, such as Statistical Parametric Mapping (SPM). FDG-PET can be carried out in small animals, but its resolution is low as compared to the size of rodent brain structures. In mouse models of AD, changes in cerebral glucose utilization are usually detected by [(14)C]-2-deoxyglucose (2DG) autoradiography, but this requires prior manual outlining of regions of interest (ROI) on selected sections. Here, we evaluate the feasibility of applying the SPM method to 3D autoradiographic data sets mapping brain metabolic activity in a transgenic mouse model of AD. We report the preliminary results obtained with 4 APP/PS1 (64+/-1 weeks) and 3 PS1 (65+/-2 weeks) mice. We also describe new procedures for the acquisition and use of "blockface" photographs and provide the first demonstration of their value for the 3D reconstruction and spatial normalization of post mortem mouse brain volumes. Despite this limited sample size, our results appear to be meaningful, consistent, and more comprehensive than findings from previously published studies based on conventional ROI-based methods. The establishment of statistical significance at the voxel level, rather than with a user-defined ROI, makes it possible to detect more reliably subtle differences in geometrically complex regions, such as the hippocampus. Our approach is generic and could be easily applied to other biomarkers and extended to other species and applications.
authors.affiliation: CEA-DSV-I2BM-MIRCen-LMN, Orsay, France. albertine.dubois@cea.fr
authors.forename: Albertine
authors.initials: A
authors.lastname: Dubois
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Hérard
authors.forename: Benoît
authors.initials: B
authors.lastname: Delatour
authors.forename: Philippe
authors.initials: P
authors.lastname: Hantraye
authors.forename: Gilles
authors.initials: G
authors.lastname: Bonvento
authors.forename: Marc
authors.initials: M
authors.lastname: Dhenain
authors.forename: Thierry
authors.initials: T
authors.lastname: Delzescaux
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000235:genetics / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D001931:Brain Mapping / Q000379:methods*; D002250:Carbon Radioisotopes; D003847:Deoxyglucose; D004195:Disease Models, Animal; D005947:Glucose / Q000378:metabolism*; D007091:Image Processing, Computer-Assisted; D051379:Mice; D008822:Mice, Transgenic; D049268:Positron-Emission Tomography; D053764:Presenilin-1 / Q000235:genetics; D019275:Radiopharmaceuticals
chemical_list: D016564:Amyloid beta-Protein Precursor; D002250:Carbon Radioisotopes; D053764:Presenilin-1; D019275:Radiopharmaceuticals; D003847:Deoxyglucose; D005947:Glucose